Unspecified T-cell acute lymphoblastic leukemia surface antigens

Unspecified T-cell acute lymphoblastic leukemia (T-ALL) surface antigens refers to a heterogeneous group of proteins expressed on the plasma membrane of malignant T-cell precursors. These antigens, which include CD7, CD5, CD1a, CD3, and CD38, are primarily utilized for the immunophenotypic diagnosis and subclassification of T-ALL (Source: StatPearls, 2023). While these markers are essential for identifying leukemic cells and monitoring minimal residual disease, they are not a single therapeutic target but rather a category of potential targets for monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapies (Source: Journal of Hematology & Oncology, 2021). A significant challenge in targeting these antigens is their frequent expression on healthy T-cells or hematopoietic stem cells, which can lead to severe on-target, off-tumor toxicities such as profound T-cell aplasia and prolonged immunosuppression (Source: Blood, 2022). Consequently, therapeutic development requires the selection of specific antigens with the highest possible leukemia-to-normal tissue expression ratio. Because this term encompasses multiple distinct proteins with varying biological roles and therapeutic profiles, it is considered an aggregate category rather than a discrete molecular target (Source: Frontiers in Immunology, 2021).

Other names

T-cell acute lymphoblastic leukemia surface markersT-ALL antigensT-lymphoblast surface proteins

Targeting specific surface proteins on malignant T-cells to induce cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct T-cell mediated lysis (Source: Nature Reviews Clinical Oncology, 2020).